Characterization of novel anti-IL-26 neutralizing monoclonal antibodies for the treatment of inflammatory diseases including psoriasis

References

• Knappe A, Hor S, Wittmann S, Fickenscher H. Induction of a novel cellular homolog of interleukin-10, AK155, by transformation of T lymphocytes with herpesvirus saimiri. J Virol. 2000;74:3881–87. doi:10.1128/jvi.74.8.3881-3887.2000.
   PubMed Web of Science ®Google Scholar
• Kotenko SV. The family of IL-10-related cytokines and their receptors: related, but to what extent? Cytokine Growth Factor Rev. 2002;13:223–40.
   PubMed Web of Science ®Google Scholar
• Donnelly RP, Sheikh F, Dickensheets H, Savan R, Young HA, Walter MR. Interleukin-26: an IL-10-related cytokine produced by Th17 cells. Cytokine Growth Factor Rev. 2010;21:393–401. doi:10.1016/j.cytogfr.2010.09.001.
   PubMed Web of Science ®Google Scholar
• Schoenborn JR, Dorschner MO, Sekimata M, Santer DM, Shnyreva M, Fitzpatrick DR, Stamatoyannopoulos JA, Wilson CB. Comprehensive epigenetic profiling identifies multiple distal regulatory elements directing transcription of the gene encoding interferon-gamma. Nat Immunol. 2007;8:732–42. doi:10.1038/ni1474.
   PubMed Web of Science ®Google Scholar
• Wolk K, Kunz S, Asadullah K, Sabat R. Cutting edge: immune cells as sources and targets of the IL-10 family members? J Immunol. 2002;168:5397–402. doi:10.4049/jimmunol.168.11.5397.
   PubMed Web of Science ®Google Scholar
• Wilson NJ, Boniface K, Chan JR, McKenzie BS, Blumenschein WM, Mattson JD, Basham B, Smith K, Chen T, Morel F, et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol. 2007;8:950–57. doi:10.1038/ni1497.
   PubMed Web of Science ®Google Scholar
• Corvaisier M, Delneste Y, Jeanvoine H, Preisser L, Blanchard S, Garo E, Hoppe E, Barre B, Audran M, Bouvard B, et al. IL-26 is overexpressed in rheumatoid arthritis and induces proinflammatory cytokine production and Th17 cell generation. PLoS Biol. 2012;10:e1001395. doi:10.1371/journal.pbio.1001395.
   PubMed Web of Science ®Google Scholar
• Che KF, Tengvall S, Levanen B, Silverpil E, Smith ME, Awad M, Vikstrom M, Palmberg L, Qvarfordt I, Skold M, et al. Interleukin-26 in antibacterial host defense of human lungs. Effects on neutrophil mobilization. Am J Respir Crit Care Med. 2014;190:1022–31. doi:10.1164/rccm.201404-0689OC.
   PubMed Web of Science ®Google Scholar
• Che KF, Kaarteenaho R, Lappi-Blanco E, Levanen B, Sun J, Wheelock A, Palmberg L, Skold CM, Linden A. Interleukin-26 production in human primary bronchial epithelial cells in response to viral stimulation: modulation by Th17 cytokines. Mol Med. 2017:23. doi:10.2119/molmed.2016.00064.
   Web of Science ®Google Scholar
• Hor S, Pirzer H, Dumoutier L, Bauer F, Wittmann S, Sticht H, Renauld JC, de Waal Malefyt R, Fickenscher H. The T-cell lymphokine interleukin-26 targets epithelial cells through the interleukin-20 receptor 1 and interleukin-10 receptor 2 chains. J Biol Chem. 2004;279:33343–51. doi:10.1074/jbc.M405000200.
   PubMed Web of Science ®Google Scholar
• Dambacher J, Beigel F, Zitzmann K, De Toni EN, Goke B, Diepolder HM, Auernhammer CJ, Brand S. The role of the novel Th17 cytokine IL-26 in intestinal inflammation. Gut. 2009;58:1207–17. doi:10.1136/gut.2007.130112.
   PubMed Web of Science ®Google Scholar
• Miot C, Beaumont E, Duluc D, Le Guillou-Guillemette H, Preisser L, Garo E, Blanchard S, Hubert Fouchard I, Creminon C, Lamourette P, et al. IL-26 is overexpressed in chronically HCV-infected patients and enhances TRAIL-mediated cytotoxicity and interferon production by human NK cells. Gut. 2015;64:1466–75. doi:10.1136/gutjnl-2013-306604.
   PubMed Web of Science ®Google Scholar
• Itoh T, Hatano R, Komiya E, Otsuka H, Narita Y, Aune TM, Dang NH, Matsuoka S, Naito H, Tominaga M, et al. Biological effects of IL-26 on T cell-mediated skin inflammation, including psoriasis. J Invest Dermatol. 2019;139:878–89. doi:10.1016/j.jid.2018.09.037.
   PubMed Web of Science ®Google Scholar
• Meller S, Di Domizio J, Voo KS, Friedrich HC, Chamilos G, Ganguly D, Conrad C, Gregorio J, Le Roy D, Roger T, et al. T(H)17 cells promote microbial killing and innate immune sensing of DNA via interleukin 26. Nat Immunol. 2015;16:970–79. doi:10.1038/ni.3211.
   PubMed Web of Science ®Google Scholar
• Dang AT, Teles RM, Weiss DI, Parvatiyar K, Sarno EN, Ochoa MT, Cheng G, Gilliet M, Bloom BR, Modlin RL. IL-26 contributes to host defense against intracellular bacteria. J Clin Invest. 2019;130:1926–39. doi:10.1172/JCI99550.
   Web of Science ®Google Scholar
• Scala E, Di Caprio R, Cacciapuoti S, Caiazzo G, Fusco A, Tortorella E, Fabbrocini G, Balato A. A new T helper 17 cytokine in hidradenitis suppurativa: antimicrobial and proinflammatory role of interleukin-26. Br J Dermatol. 2019. doi:10.1111/bjd.17854.
   Web of Science ®Google Scholar
• Fujii M, Nishida A, Imaeda H, Ohno M, Nishino K, Sakai S, Inatomi O, Bamba S, Kawahara M, Shimizu T, et al. Expression of Interleukin-26 is upregulated in inflammatory bowel disease. World J Gastroenterol. 2017;23:5519–29. doi:10.3748/wjg.v23.i30.5519.
   PubMed Web of Science ®Google Scholar
• Heftdal LD, Andersen T, Jaehger D, Woetmann A, Ostgard R, Kenngott EE, Syrbe U, Sieper J, Hvid M, Deleuran B, et al. Synovial cell production of IL-26 induces bone mineralization in spondyloarthritis. J Mol Med (Berl). 2017;95:779–87. doi:10.1007/s00109-017-1528-2.
   PubMed Web of Science ®Google Scholar
• Esendagli G, Kurne AT, Sayat G, Kilic AK, Guc D, Karabudak R. Evaluation of Th17-related cytokines and receptors in multiple sclerosis patients under interferon beta-1 therapy. J Neuroimmunol. 2013;255:81–84. doi:10.1016/j.jneuroim.2012.10.009.
   PubMed Web of Science ®Google Scholar
• Konradsen JR, Nordlund B, Levanen B, Hedlin G, Linden A. The cytokine interleukin-26 as a biomarker in pediatric asthma. Respir Res. 2016;17:32. doi:10.1186/s12931-016-0351-6.
   PubMed Web of Science ®Google Scholar
• Kaabachi W, Bouali E, Berraies A, Dhifallh IB, Hamdi B, Hamzaoui K, Hamzaoui A. Interleukin-26 is overexpressed in Behcet’s disease and enhances Th17 related -cytokines. Immunol Lett. 2017;190:177–84. doi:10.1016/j.imlet.2017.08.008.
   PubMed Web of Science ®Google Scholar
• Caiazzo G, Di Caprio R, Lembo S, Raimondo A, Scala E, Patruno C, Balato A. IL-26 in allergic contact dermatitis: resource in a state of readiness. Exp Dermatol. 2018;27:681–84. doi:10.1111/exd.13521.
   PubMed Web of Science ®Google Scholar
• Savchenko L, Mykytiuk M, Cinato M, Tronchere H, Kunduzova O, Kaidashev I. IL-26 in the induced sputum is associated with the level of systemic inflammation, lung functions and body weight in COPD patients. Int J Chron Obstruct Pulmon Dis. 2018;13:2569–75. doi:10.2147/COPD.S164833.
   PubMed Web of Science ®Google Scholar
• Collins PL, Chang S, Henderson M, Soutto M, Davis GM, McLoed AG, Townsend MJ, Glimcher LH, Mortlock DP, Aune TM. Distal regions of the human IFNG locus direct cell type-specific expression. J Immunol. 2010;185:1492–501. doi:10.4049/jimmunol.1000124.
   PubMed Web of Science ®Google Scholar
• Collins PL, Henderson MA, Aune TM. Lineage-specific adjacent IFNG and IL26 genes share a common distal enhancer element. Genes Immun. 2012;13:481–88. doi:10.1038/gene.2012.22.
   PubMed Web of Science ®Google Scholar
• Ohnuma K, Hatano R, Aune TM, Otsuka H, Iwata S, Dang NH, Yamada T, Morimoto C. Regulation of pulmonary graft-versus-host disease by IL-26+CD26+CD4 T lymphocytes. J Immunol. 2015;194:3697–712. doi:10.4049/jimmunol.1402785.
   PubMed Web of Science ®Google Scholar
• Ohnuma K, Hatano R, Itoh T, Iwao N, Dang NH, Morimoto C. Role of IL-26+CD26+CD4 T cells in pulmonary chronic graft-versus-host disease and treatment with caveolin-1-Ig Fc conjugate. Crit Rev Immunol. 2016;36:239–67. doi:10.1615/CritRevImmunol.2016018772.
   PubMed Web of Science ®Google Scholar
• You W, Tang Q, Zhang C, Wu J, Gu C, Wu Z, Li X. IL-26 promotes the proliferation and survival of human gastric cancer cells by regulating the balance of STAT1 and STAT3 activation. PloS One. 2013;8:e63588. doi:10.1371/journal.pone.0063588.
   PubMed Web of Science ®Google Scholar
• Stephen-Victor E, Fickenscher H, Bayry J. IL-26: an emerging proinflammatory member of the IL-10 cytokine family with multifaceted actions in antiviral, antimicrobial, and autoimmune responses. PLoS Pathog. 2016;12:e1005624. doi:10.1371/journal.ppat.1005624.
   PubMed Web of Science ®Google Scholar
• Boehncke WH, Schon MP. Psoriasis. Lancet. 2015;386:983–94. doi:10.1016/S0140-6736(14)61909-7.
   PubMed Web of Science ®Google Scholar
• Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature. 2007;445:866–73. doi:10.1038/nature05663.
   PubMed Web of Science ®Google Scholar
• Golden JB, McCormick TS, Ward NL. IL-17 in psoriasis: implications for therapy and cardiovascular co-morbidities. Cytokine. 2013;62:195–201. doi:10.1016/j.cyto.2013.03.013.
   PubMed Web of Science ®Google Scholar
• Suzuki T, Hirakawa S, Shimauchi T, Ito T, Sakabe J, Detmar M, Tokura Y. VEGF-A promotes IL-17A-producing gammadelta T cell accumulation in mouse skin and serves as a chemotactic factor for plasmacytoid dendritic cells. J Dermatol Sci. 2014;74:116–24. doi:10.1016/j.jdermsci.2013.12.013.
   PubMed Web of Science ®Google Scholar
• Honorati MC, Neri S, Cattini L, Facchini A. Interleukin-17, a regulator of angiogenic factor release by synovial fibroblasts. Osteoarthritis Cartilage. 2006;14:345–52. doi:10.1016/j.joca.2005.10.004.
   PubMed Web of Science ®Google Scholar
• Reszke R, Szepietowski JC. Secukinumab in the treatment of psoriasis: an update. Immunotherapy. 2017;9:229–38. doi:10.2217/imt-2016-0128.
   PubMed Web of Science ®Google Scholar
• Ariza ME, Williams MV, Wong HK. Targeting IL-17 in psoriasis: from cutaneous immunobiology to clinical application. Clin Immunol. 2013;146:131–39. doi:10.1016/j.clim.2012.12.004.
   PubMed Web of Science ®Google Scholar
• Interleukin VM. 17 is a chief orchestrator of immunity. Nat Immunol. 2017;18:612–21. doi:10.1038/ni.3742.
   PubMed Web of Science ®Google Scholar
• Gordon KB, Blauvelt A, Papp KA, Langley RG, Luger T, Ohtsuki M, Reich K, Amato D, Ball SG, Braun DK, et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375:345–56. doi:10.1056/NEJMoa1512711.
   PubMed Web of Science ®Google Scholar
• Esfahani K, Miller WH Jr. Reversal of autoimmune toxicity and loss of tumor response by interleukin-17 blockade. N Engl J Med. 2017;376:1989–91. doi:10.1056/NEJMc1703047.
   PubMed Web of Science ®Google Scholar
• Heidenreich R, Rocken M, Ghoreschi K. Angiogenesis drives psoriasis pathogenesis. Int J Exp Pathol. 2009;90:232–48. doi:10.1111/j.1365-2613.2009.00669.x.
   PubMed Web of Science ®Google Scholar
• Poli C, Augusto JF, Dauve J, Adam C, Preisser L, Larochette V, Pignon P, Savina A, Blanchard S, Subra JF, et al. IL-26 confers proinflammatory properties to extracellular DNA. J Immunol. 2017;198:3650–61. doi:10.4049/jimmunol.1600594.
   PubMed Web of Science ®Google Scholar
• Hatano R, Yamada T, Madokoro H, Otsuka H, Komiya E, Itoh T, Narita Y, Iwata S, Yamazaki H, Matsuoka S, et al. Development of novel monoclonal antibodies with specific binding affinity for denatured human CD26 in formalin-fixed paraffin-embedded and decalcified specimens. PloS One. 2019;14:e0218330. doi:10.1371/journal.pone.0218330.
   PubMed Web of Science ®Google Scholar
• Hatano R, Ohnuma K, Otsuka H, Komiya E, Taki I, Iwata S, Dang NH, Okumura K, Morimoto C. CD26-mediated induction of EGR2 and IL-10 as potential regulatory mechanism for CD26 costimulatory pathway. J Immunol. 2015;194:960–72. doi:10.4049/jimmunol.1402143.
   PubMed Web of Science ®Google Scholar
• Alrefai H, Muhammad K, Rudolf R, Pham DA, Klein-Hessling S, Patra AK, Avots A, Bukur V, Sahin U, Tenzer S, et al. NFATc1 supports imiquimod-induced skin inflammation by suppressing IL-10 synthesis in B cells. Nat Commun. 2016;7:11724. doi:10.1038/ncomms11724.
   PubMed Web of Science ®Google Scholar